Trial · NCT02419937
Short-Term Application of Tocilizumab Following Myocardial Infarction
NCT02419937, Not applicable, Completed, Keesler Air Force Base Medical Center; results first posted 2017-11-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Short-Term Application of Tocilizumab Following Myocardial Infarction. Trials, record NCT02419937. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02419937
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Short-Term Application of Tocilizumab Following Myocardial Infarction
- NCT number
- NCT02419937
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 28 participants, actual
- Lead sponsor
- Keesler Air Force Base Medical Center
- Conditions
- Myocardial Infarction
- Interventions
- Tocilizumab, Placebo
- First posted
- 2015-04-17
- Last updated
- 2017-11-17
- Results first posted
- 2017-11-17
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Major Adverse Cardiovascular Events (MACE) | 30 days after one time injection | 30 day rate of major adverse cardiac events (MACE) following administration of Tocilizumab subcutaneously single dose within 24 hours of NSTEMI or STEMI as compared to administration of placebo |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Major Adverse Cardiovascular Events (MACE) | 30 days after one time injection | Major Adverse Cardiac Events (MACE) for those gathered 30 days after receiving medication or placebo | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Major Adverse Cardiovascular Events (MACE) | Tocilizumab | Death | 0 | Participants | |
| Number of Participants With Major Adverse Cardiovascular Events (MACE) | Placebo | Death | 0 | Participants | |
| Number of Participants With Major Adverse Cardiovascular Events (MACE) | Tocilizumab | Recurrent Myocardial Infarction | 2 | Participants | |
| Number of Participants With Major Adverse Cardiovascular Events (MACE) | Placebo | Recurrent Myocardial Infarction | 1 | Participants | |
| Number of Participants With Major Adverse Cardiovascular Events (MACE) | Tocilizumab | Dysrhythmia | 2 | Participants | |
| Number of Participants With Major Adverse Cardiovascular Events (MACE) | Placebo | Dysrhythmia | 1 | Participants | |
| Number of Participants With Major Adverse Cardiovascular Events (MACE) | Tocilizumab | Septal/Valve Rupture | 1 | Participants | |
| Number of Participants With Major Adverse Cardiovascular Events (MACE) | Placebo | Septal/Valve Rupture | 1 | Participants | |
| Number of Participants With Major Adverse Cardiovascular Events (MACE) | Tocilizumab | Pericarditis | 2 | Participants | |
| Number of Participants With Major Adverse Cardiovascular Events (MACE) | Placebo | Pericarditis | 0 | Participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tocilizumab | 12 | |
| Overall Study | STARTED | Placebo | 16 | |
| Overall Study | COMPLETED | Tocilizumab | 11 | |
| Overall Study | COMPLETED | Placebo | 16 | |
| Overall Study | NOT COMPLETED | Tocilizumab | 1 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Symptomatic bradycardia | Cardiac disorders | Tocilizumab | 0 | 11 | 0 |
| serious | Symptomatic bradycardia | Cardiac disorders | Placebo | 1 | 16 | 1 |
| serious | Symptomatic Hypotension | Cardiac disorders | Tocilizumab | 0 | 11 | 0 |
| serious | Symptomatic Hypotension | Cardiac disorders | Placebo | 1 | 16 | 1 |
| serious | Gross Hematuria | General disorders | Tocilizumab | 1 | 11 | 1 |
| serious | Gross Hematuria | General disorders | Placebo | 0 | 16 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Tocilizumab | 0 | 11 |
| Total, all-cause mortality | Placebo | 0 | 16 |
| Total, other adverse events | Tocilizumab | 0 | 11 |
| Total, other adverse events | Placebo | 0 | 16 |
| Total, serious adverse events | Tocilizumab | 1 | 11 |
| Total, serious adverse events | Placebo | 2 | 16 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 29067495 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Tocilizumab vs Placebo: deaths from any cause | Trial comparisons |
| Tocilizumab vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02419937
GET https://conductscience.org/api/trials/v1/NCT02419937/registered